NCT04815551View on ClinicalTrials.gov

A Phase 1 Study of AV-380 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

January 14, 2022

Study Completion Date

January 14, 2022

Conditions
Cachexia
Interventions
DRUG

AV-380

AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

DRUG

Placebo

Placebo is sterile liquid for IV infusion.

Trial Locations (1)

07103

Biotrial Inc., Newark

Sponsors
All Listed Sponsors
lead

AVEO Pharmaceuticals, Inc.

INDUSTRY